Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Solange Peters, Richard Cathomas et al.|The Lancet|2015Cited by 392
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|European Journal of Cancer|2017Cited by 27
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).Miklos Pless, Roger Stupp, Hans‐Beat Ris et al.|Journal of Clinical Oncology|2013Cited by 19
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|Journal of Clinical Oncology|2014Cited by 5
Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).Dieter Koeberle, G. Bodoky, Jean‐François Dufour et al.|Journal of Clinical Oncology|2014Cited by 5